The Market Is Flashing Warning Signals Not Seen in Years. Here’s Why I Just Bought 3 of SCHD’s Dividend Kings.

The Shiller CAPE ratio is approaching 42, its second-highest reading in 150 years, prompting the author to add defensive dividend stocks rather than move to cash. Abbott yields 2.5% and trades at 18.5x forward earnings; P&G yields nearly 3% at less than 22x, while PepsiCo yields more than 4.5% at 15x. The author cites their long dividend-growth records and resilient businesses, while noting near-term pricing headwinds at P&G and PepsiCo.

Analysis

The portfolio implication is more credible than the article’s valuation-timing signal: a high CAPE may flag weak long-run prospective market returns, but it is not a reliable near-term crash trigger. Dividend growth also does not immunize these stocks from multiple compression; stable cash flows can still lose value when discount rates rise. The “defensive” label is uneven: ABT’s healthcare mix may diversify consumer exposure, while PG and PEP share sensitivity to household trade-down, retailer bargaining power, and input-cost or pricing pressure. A consumer slowdown could therefore hit both at once, and competition from private label may limit the ability to restore margins through price increases.

SCHD’s ownership is not independent fundamental validation. If defensive-income positioning becomes crowded, ETF outflows or a rotation toward higher-yielding cash and bonds could pressure the same holdings. The article’s cited forward multiples, yields, and growth expectations should be checked against current filings and estimates before sizing; none alone establishes a margin of safety.

Near term, rates and relative flows may dominate earnings. Over 1–3 months, watch company guidance on volume, pricing, and margins; over 6–18 months, the thesis depends on earnings compounding and dividends growing without leverage or payout strain. The contrarian risk is that investors pay too much for perceived safety while underestimating duration and consumer-demand exposure.

Key Decisions for Investors

• Do not short the broad market solely on CAPE. Treat it as a reason to moderate equity beta, not a dated catalyst; reconsider if earnings breadth and forward guidance deteriorate materially.
• For defensive exposure, consider a staged, diversified allocation across ABT, PG, and PEP rather than a concentrated SCHD-style basket. Verify current valuation, dividend coverage, debt, and estimate revisions before entry.
• Monitor PG and PEP quarterly volume, realized pricing, gross-margin trends, and retailer/private-label commentary. Persistent volume declines or weaker margin guidance would falsify the assumption that pricing can offset cost and demand pressure.
• Track ABT’s segment growth and product/regulatory updates separately from the consumer-staples thesis; a deterioration in device or diagnostics demand would weaken its diversification role. No options trade is warranted without a defined catalyst and verified current pricing.